GlaxoSmithKline Czech Republic - Net Debt Growth

GlaxoSmithKline CR`s Net Debt Growth reached -40.3 % in 2017. This is 25.6 % more than in the previous year.

$1.99

Buy Net Debt Growth data for GlaxoSmithKline Czech Republic.

$19.99

Buy all data for GlaxoSmithKline Czech Republic.

from $199/month

Buy annual subscriptions for all our products.

 
Company Unit 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
Amgen Czech Republic ... ... ... ... ...           ... ... ... -17,482 83.3    
Bayer Czech Republic ... ... ...               -71.1 -78.0 -272 13.5 595    
GlaxoSmithKline Czech Republic ... ... ...               -18.8 76.2 33.3 -100 266,920    
Merck Czech Republic ... ...                 13.5 -7.53 18.5 -86.2 -113    
Novartis Czech Republic                     141 -75.5 -109 -2,141 -102    
Pfizer Czech Republic ... ...                 -703 -113 -72.3 1,069 -98.5    
Roche Czech Republic ... ... ...               -100 -40,192 88.9 90.0 21.9   ...
Sanofi-Aventis Czech Republic ... ... ... ...             -4.00 14.4 -34.2 -46.3 -14.4    
Servier Czech Republic ... ... ... ... ... ... ... ... ... ... ... ... 41.6 -14.0 -44.7    
Walmark ... ... ...               -41.2 340 -22.8 -12.0 166